加味四妙丸联合西药治疗湿热瘀滞证ⅢA型前列腺炎临床研究  

Clinical Study on Modified Simiao Pills Combined with Western Medicine for Type ⅢA Prostatitis with Dampness-Heat Stasis and Stagnation Syndrome

作　　者：张莎莎[1] 张旭[1] 周立斌 吕文良[3] ZHANG Shasha;ZHANG Xu;ZHOU Libin;LYU Wenliang

机构地区：[1]湖州市第一人民医院,浙江湖州313000 [2]宁波市医疗中心李惠利医院(宁波大学附属李惠利医院),浙江宁波315040 [3]中国中医科学院广安门医院,北京100053

出　　处：《新中医》2021年第17期62-65,共4页New Chinese Medicine

基　　金：浙江省医药卫生科技项目(2019KY603,2020KY858);宁波市自然基金项目(2019A610256)。

摘　　要：目的:观察加味四妙丸联合西药治疗湿热瘀滞证ⅢA型前列腺炎的临床疗效。方法:选取64例湿热瘀滞证ⅢA型前列腺炎患者,按随机数字表法分为研究组及对照组各32例。对照组给予左氧氟沙星片、盐酸坦洛新缓释片治疗,研究组在对照组治疗的基础上给予加味四妙丸。2组均治疗4周。观察2组临床疗效,比较2组治疗前后美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、前列腺液中白细胞计数等级、卵磷脂小体计数等级、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、环氧化酶-2 (COX-2)的水平变化。观察2组治疗期间不良反应情况。结果:研究组总有效率为87.5%,高于对照组的65.6%,差异有统计学意义(P<0.05)。治疗后,2组NIH-CPSI总分均较治疗前下降(P<0.05),研究组NIH-CPSI总分低于对照组(P<0.05)。治疗后,2组炎症程度均较治疗前减轻(P<0.05),研究组炎症减轻程度优于对照组(P<0.05)。治疗后,2组前列腺液中IL-1β、TNF-α、COX-2水平均较治疗前下降(P<0.05),研究组上述3项水平均低于对照组(P<0.05)。2组患者耐受性较好,在治疗过程中均未出现严重不良反应,肝肾功能未见明显异常。结论:加味四妙丸联合西药治疗湿热瘀滞证ⅢA型前列腺炎可改善前列腺炎的炎症程度,有效缓解临床症状,提高临床疗效,为中西医结合治疗慢性前列腺炎提供新的治疗方案。Objective:To observe the clinical effect of modified Simiao pills combined with western medicine for type IIIA prostatitis with dampness-heat stasis and stagnation syndrome. Methods: A total of 64 cases of patients with type IIIA prostatitis with dampness-heat stasis and stagnation syndrome were selected and divided into the study group and the control group according to the random number table method,32 cases in each group. The control group was treated with levofloxacin tablets and tamsulosin hydrochloride sustained-release tablets, and the study group was additionally given modified Simiao pills based on the treatment of the control group. Both groups were treated for four weeks. The clinical effect in the two groups was observed. Before and after treatment,the changes in National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI) and the levels of white blood cell count,lecithin corpuscle count,Interleukin-1β(IL-1β)、Tumor Necrosis Factor-α(TNF-α)、 Cyclooxygenase-2(COX-2) in prostatic fluid in the two groups were compared. Adverse reactions in the two gropus were observed. Results:The total effective rate was 87.5% in the study group,higher than that of 65.6% in the control group,the difference being significant(P<0.05). After treatment,the total scores of NIH-CPSI in the two groups were decreased when compared with those before treatment(P<0.05),and the total score of NIH-CPSI in the study group was lower than that in the control group(P<0.05). After treatment, the severity of inflammation in the two groups was reduced when compared with that before treatment(P<0.05),and the reduction in the study group was better than that in the control group(P<0.05). After treatment,the levels of IL-1β,TNF-α and COX-2 in prostatic fluid in the two groups were decreased when compared with those before treatment(P<0.05),and the above three levels in the study group were lower than those in the control group(P<0.05). Patients in the two groups had good tolerance,and so there was no serious adverse reac

关 键 词：ⅢA型前列腺炎 湿热瘀滞证 加味四妙丸 左氧氟沙星 盐酸坦洛新 

分 类 号：R697.33[医药卫生—泌尿科学]